Key Points
The transaction involved 38,900 shares valued at ~$1.8 million based on a weighted average price of $46.78 per share.
The executive traded shares equal to 11% of the equity stake held before the filing.
The disposal followed a 50% one-year total return for the stock as of the September 11, 2026 transaction date.
John C.M. Farquhar, Chief Executive Officer of HeartFlow, Inc. (NASDAQ:HTFL), executed a sale of 38,900 shares of common stock, according to a September 14, 2026 SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $1.8 million |
| Shares sold | 38,900 |
| Post-transaction shares (directly held) | 321,914 |
| Post-transaction value | $16.06 million |
Transaction value based on SEC Form 4 weighted average sale price ($46.78); post-transaction value based on September 11, 2026 market close ($49.88).
Key questions
- When was the trading plan governing this transaction established?
The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted by the executive on September 12, 2025. - What is the scope of the executive's remaining equity position?
Following the transaction, the executive maintains a direct stake of ~322,000 shares, representing 0.37% of the company, and also holds derivative securities. - What were the execution details regarding the share price?
The transaction was executed in multiple trades at prices ranging from $45.43 to $47.78, resulting in the reported weighted average of $46.78 per share. - How does the transaction price compare to recent market levels?
The executive realized ~$1.8 million at the $46.78 weighted average price, while the common stock was priced at $49.54 as of the September 14, 2026 market close.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-14) | $49.54 |
| Market Capitalization | $4.3 billion |
| Revenue (TTM) | $212.1 million |
| Net Income (TTM) | -$118.4 million |
Company Snapshot
- HeartFlow develops and commercializes the HeartFlow Platform, an artificial intelligence-powered diagnostic solution that generates three-dimensional digital replicas of patient hearts from coronary computed tomography angiography scans to enable non-surgical diagnosis and management of coronary artery disease.
- The company generates revenue through licensing its proprietary HeartFlow Platform to healthcare providers and institutions, leveraging advanced computational fluid dynamics and machine learning algorithms to deliver personalized cardiac diagnostics and clinical decision support.
- HeartFlow primarily serves cardiologists, interventional radiologists, and hospital systems globally, targeting healthcare institutions seeking to improve diagnostic accuracy and reduce unnecessary invasive procedures in coronary artery disease management.
HeartFlow operates as a global medical technology company with a market cap of $4.3 billion, demonstrating significant investor confidence in its AI-driven cardiac diagnostic platform. The company has achieved trailing 12-month revenue of $212.1 million while investing substantially in research and development, reflecting its growth-stage positioning within the healthcare information services sector.
HeartFlow's competitive advantage stems from its proprietary computational fluid dynamics technology and clinical validation, positioning it as a differentiated provider in the non-invasive coronary artery disease diagnosis market.
What this transaction means for investors
CEO John Farquhar's Sept. 10 and Sept. 11 sale of HeartFlow stock came not long after shares reached a 52-week high of $51.78 on Sept. 2. The timing was fortuitous, but not a market-timed investment decision, since it was executed as part of a pre-established Rule 10b5-1 plan. This makes the sale a non-discretionary transaction.
Farquhar maintains over 320,000 directly held shares post-disposition. This is a sizable equity stake that ensures his continued alignment with shareholder interests.
HeartFlow stock is up as the company's technology looks poised to continue capturing more market share. Independent clinical trial data revealed HeartFlow's medical technology reduces unnecessary invasive heart procedures by nearly half.
Moreover, the company posted revenue of $64.1 million in the second quarter. This sum represents a 48% year-over-year increase as adoption of its tech ramps up. Its success to date led management to raise its 2026 full-year sales guidance to a range between $246 million and $250 million, compared to $176 million in 2025.
Robert Izquierdo has positions in HeartFlow. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.